Search results
Found 16154 matches for
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
SINAPPS2 Background & PPiP2 Recruitment Training Confirmation
The SINAPPS2 Trial is inviting people with acute psychosis symptom(s) and anti-neuronal membrane antibodies who have been identified through PPiP2 study to consent the trial and help testing the efficacy and safety of immunotherapy for antibody-associated psychosis.